<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530683</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-622-01</org_study_id>
    <nct_id>NCT03530683</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma</brief_title>
  <acronym>TTI-622-01</acronym>
  <official_title>A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in
      Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-622 in subjects with relapsed or refractory lymphoma or myeloma.

      TTI-622 (SIRPα-IgG4 Fc), is a soluble recombinant fusion protein created by directly linking
      the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain
      of human immunoglobulin (IgG4). TTI-622 acts by binding human CD47 and preventing it from
      delivering an inhibitory &quot;do not eat&quot; (anti phagocytic) signal to macrophages.

      This trial will be conducted in 2 phases: Phase 1a (Dose-escalation phase) and Phase 1b
      (Expansion Combination Treatment).

      In the Dose-escalation Phase (phase 1a), subjects with lymphoma will be enrolled in
      sequential dose cohorts to receive TTI-622 to characterize safety, tolerability,
      pharmacokinetics, and the maximum-tolerated dose (MTD).

      In the Combination Treatment Phase (phase 1b), TTI-622 will be given to subjects with
      CD20-positive lymphoma, classic Hodgkin lymphoma and Myeloma, in combination with other
      anti-cancer drugs, to further define safety and to characterize efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>36</time_frame>
    <description>To characterize the safety profile and dose-limiting toxicities (DLTs) of TTI-622.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>TTI-622 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Phase will include multiple doses of TTI-622</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-622 + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CD20 positive lymphoma may enter the TTI-622 + rituximab combination cohort; rituximab administered according to the institutional standard of care in accordance with the current FDA-approved package insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-622 + PD-1/PD-L1 Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with classic Hodgkin Lymphoma may enroll in this cohort and will receive TTI-622 in combination with either nivolumab administered per institutional standard of care in accordance with the current FDA-approved package insert or pembrolizumab administered per institutional standard of care in accordance with the current FDA-approved package insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTI-622 + Proteasome-Inhibitor Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with myeloma will receive TTI-622 in addition to a standard NCCN guideline recommended proteasome inhibitor (either bortezomib or carfilzomib) + dexamethasone-containing regimen administered per institutional standard of care in accordance with the current FDA-approved package insert.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-622 Monotherapy</intervention_name>
    <description>TTI-622 (SIRPα-IgG4 Fc), is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG4). TTI-622 acts by binding human CD47 and preventing it from delivering an inhibitory &quot;do not eat&quot; (anti phagocytic) signal to macrophages</description>
    <arm_group_label>TTI-622 Monotherapy</arm_group_label>
    <other_name>SIRPα-IgG4 Fc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-622 + Rituximab</intervention_name>
    <description>TTI-622 + Rituximab combination therapy.</description>
    <arm_group_label>TTI-622 + Rituximab</arm_group_label>
    <other_name>SIRPα-IgG4 Fc + Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-622 + PD-1/PD-L1 Inhibitor</intervention_name>
    <description>TTI-622 plus Nivolumab or Pembrolizumab combination therapy</description>
    <arm_group_label>TTI-622 + PD-1/PD-L1 Inhibitor</arm_group_label>
    <other_name>SIRPα-IgG4 Fc + PD-1/PD-L1 Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-622 + Proteasome-inhibitor Regimen</intervention_name>
    <description>TTI-622 plus a proteasome-inhibitor regimen (bortezomib plus dexamethasone or carfilzomib plus dexamethasone).</description>
    <arm_group_label>TTI-622 + Proteasome-Inhibitor Regimen</arm_group_label>
    <other_name>SIRPα-IgG4 Fc + a Proteasome-inhibitor Regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory hematologic malignancy (lymphoma or multiple myeloma) that has
             progressed, or is currently progressing with standard anticancer therapy or for which
             no other approved therapy exist. Lymphoma patients must have failed at least 2
             standard anticancer therapies, and multiple myeloma patients must have failed at least
             3 standard anticancer therapies.

          2. Advanced measurable malignancy

          3. Adequate hematologic status

          4. Adequate coagulation function

          5. Adequate hepatic function

          6. Adequate renal function

        Exclusion Criteria:

          1. Known, current central nervous system disease involvement or untreated brain
             metastases

          2. Hematopoietic cell transplant or other cellular based therapy within 30 days before
             the planned start of study treatment or patients with active graft-vs-host disease
             with the exception of Grade 1 skin involvement

          3. History of hemolytic anemia or bleeding diathesis or positive direct antiglobulin
             test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penka Petrova, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trillium Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Marshall</last_name>
    <phone>(416) 595-0627</phone>
    <phone_ext>233</phone_ext>
    <email>andrew@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penka Petrova, PhD</last_name>
    <phone>(416) 595-0627</phone>
    <phone_ext>234</phone_ext>
    <email>penka@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silva Pregja</last_name>
      <phone>313-576-8673</phone>
      <email>pregjas@karmanos.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

